CoChat
Sign Up
Cited by 33Electrochemical sensors and biosensorsDiabetes Management and ResearchNeuroscience and Neural Engineering

Inflammation and Glucose Sensors: Use of Dexamethasone to Extend Glucose Sensor Function and Life Span in Vivo

Open access
Klueh, Ulrike, Kaur, Manjot, Montrose, David C., Kreutzer, Donald L.·2007·Journal of Diabetes Science and Technology
DOI 10.1177/193229680700100407PMC PMC2769643
Open this paper in CoChat — free account

Abstract

Background: It has been generally accepted that the acute loss of sensor function is the consequence of sensor biofouling as a result of inflammation induced at sites of sensor implantation, as well as tissue trauma induced by the sensor and its implantation. Because anti-inflammatory therapies are used routinely to control inflammation in a wide variety of diseases, we hypothesized that anti-inflammatory therapy would likely extend glucose sensor function in vivo. To test this hypothesis, we utilized our recently developed mouse model of implantable glucose sensors and the potent anti-inflammatory steroid dexamethasone (DEX). Method: For this study, glucose sensors were implanted subcutaneously into the head and neck area of mice and sensor function was determined up to 14 days postimplantation. These mice received a daily intraperitoneal injection of DEX at a dose of 1, 6, or 10 mg/kg body weight. Results: Mice not treated with DEX lost sensor functionality very rapidly, usually within the first 24 hours postimplantation. Mice treated with DEX at the various doses had an increased sensor life span of up to 2 weeks postimplantation. Additionally, sensitivity was maintained in DEX-treated mice as compared to control mice (non-DEX treated). Histologic evaluation of tissue surrounding the site of sensor implantation had almost no inflammatory cells in DEX-treated mice, whereas control mice had an intense band of inflammation surrounding the site of sensor implantation. Conclusion: To our knowledge this is the first study directly demonstrating that anti-inflammatory therapy can extend glucose sensor function in vivo and supports the key role of inflammation in loss of sensor function in vivo, as well as the uses of anti-inflammatory therapy as a potential key adjuvant in enhancing glucose sensor function and life span in vivo.

Integrity signals

Registry

Crossref · 10.1177/193229680700100407

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Within 24 h, biosensors in control mice had large reductions in sensitivity, while mice receiving daily dexamethasone injection at the sensor site sustained sensitivity and functionality through 2 weeks regardless of dexamethasone concentration.

    “Within 24 h biosensors in control mice suffered large reductions in sensitivity while mice receiving the daily DX injection at the sensor site experienced sustained sensitivity and functionality through 2 weeks, regardless of DX concentration.192”

    From Biocompatible Materials for Continuous Glucose Monitoring Devices (2013) · cites this paper as [192]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Klueh, U., Kaur, M., Montrose, D. C., & Kreutzer, D. L.
Affiliations
University of Connecticut (US)
Corresponding author
Klueh, Ulrike
ORCID
Venue
Journal of Diabetes Science and Technology
Publisher
SAGE Publications
Published
2007-07
Volume
1
Issue
4
Pages
496-504
ISSN
1932-2968 (ISSN-L)
DOI
10.1177/193229680700100407
PMC
PMC2769643
OpenAlex
W2137585122
Cited by
33
References
16
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 2 · 2014: 1 · 2013: 3
FWCI
0.95
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Diabetes Science and Technology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Engineering › Electrical and Electronic Engineering › Electrochemical sensors and biosensors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neural Engineering
Keywords
implantable glucose sensor, dexamethasone, anti-inflammatory therapy, inflammation, sensor sensitivity, subcutaneous implantation, tissue inflammation, diabetes monitoring

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review